安旭生物
(688075)
| 流通市值：49.28亿 | | | 总市值：49.28亿 |
| 流通股本：1.27亿 | | | 总股本：1.27亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 325,286,887.42 | 229,747,240.9 | 115,296,526.87 | 540,698,462.1 |
| 营业收入 | 325,286,887.42 | 229,747,240.9 | 115,296,526.87 | 540,698,462.1 |
| 二、营业总成本 | 392,903,928.66 | 257,664,669.31 | 121,733,021.18 | 502,118,745.92 |
| 营业成本 | 192,489,887.23 | 139,893,380.26 | 66,503,782.6 | 329,275,112.29 |
| 税金及附加 | 31,360,037.43 | 10,320,644.81 | 2,017,173.67 | 6,713,216.98 |
| 销售费用 | 39,442,184.06 | 27,195,877.65 | 15,621,441.77 | 49,326,995.28 |
| 管理费用 | 38,137,945.52 | 22,987,458.38 | 10,391,007.73 | 54,101,092.92 |
| 研发费用 | 63,702,440.14 | 47,409,960.28 | 25,058,704.57 | 101,079,334.64 |
| 财务费用 | 27,771,434.28 | 9,857,347.94 | 2,140,910.84 | -38,377,006.19 |
| 其中:利息费用 | - | 1,004.27 | - | - |
| 其中:利息收入 | -1,834,015.85 | -1,112,596.77 | -392,745.68 | - |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 32,452,856.8 | 22,444,815.69 | 11,317,050.23 | 63,426,961.5 |
| 加:投资收益 | 89,864,833.01 | 59,702,962.11 | 28,056,552.8 | 118,212,228.95 |
| 资产处置收益 | 130,444.56 | 131,398.95 | 159,342.19 | 4,610,768.06 |
| 资产减值损失(新) | - | - | - | -12,777,723.36 |
| 信用减值损失(新) | -1,673,669.58 | -1,673,669.58 | - | -12,550,014.6 |
| 其他收益 | 5,594,830.22 | 4,131,873.2 | 1,725,120.33 | 8,080,908.62 |
| 营业利润平衡项目 | 0.01 | 0 | 0.01 | 0 |
| 四、营业利润 | 58,752,253.78 | 56,819,951.96 | 34,821,571.25 | 207,582,845.35 |
| 加:营业外收入 | 5,528,902.88 | 4,707,679.88 | 54,346.4 | 3,525,594.15 |
| 减:营业外支出 | 44,443.35 | 36,770.76 | 35,969.92 | 468,351.54 |
| 五、利润总额 | 64,236,713.31 | 61,490,861.08 | 34,839,947.73 | 210,640,087.96 |
| 减:所得税费用 | -71,352 | 2,306,148.84 | 612,529.3 | 18,403,120.32 |
| 六、净利润 | 64,308,065.31 | 59,184,712.24 | 34,227,418.43 | 192,236,967.64 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 64,308,065.31 | 59,184,712.24 | 34,227,418.43 | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 64,358,593.74 | 59,305,890.78 | 34,029,618.77 | 192,295,303.31 |
| 少数股东损益 | -50,528.43 | -121,178.54 | 197,799.66 | -58,335.67 |
| 扣除非经常损益后的净利润 | 17,639,112.61 | 23,586,168.33 | 22,760,297.27 | 37,897,947.37 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.51 | 0.47 | 0.27 | 1.51 |
| (二)稀释每股收益 | 0.51 | 0.47 | 0.27 | 1.51 |
| 八、其他综合收益 | -3,687,365.57 | -2,142,147.47 | -1,895,802.41 | 3,504,624.29 |
| 归属于母公司股东的其他综合收益 | -3,687,365.57 | -2,142,147.47 | -1,895,802.41 | 3,504,624.29 |
| 九、综合收益总额 | 60,620,699.74 | 57,042,564.77 | 32,331,616.02 | 195,741,591.93 |
| 归属于母公司股东的综合收益总额 | 60,671,228.17 | 57,163,743.31 | 32,133,816.36 | 195,799,927.6 |
| 归属于少数股东的综合收益总额 | -50,528.43 | -121,178.54 | 197,799.66 | -58,335.67 |
| 公告日期 | 2025-10-31 | 2025-08-20 | 2025-04-30 | 2025-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |